Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The acquisition of SPR Therapeutics will allow Medtronic to expand its portfolio of neuromodulator medical devices. The deal is expected to close in 2027.
These third-party marketers earn commissions from their insurer clients not only upon initial signups but also every time “their” enrollees renew without changing plans.
The agency cited free speech as its reasoning for rescinding the long-standing policy. While in place, the rule barred companies that agreed to settlements with the Securities and Exchange Commission from publicly denying allegations made by regulators.
RadNet Chaiman and CEO Howard Berger, MD, explains why the company has invested tens of millions into DeepHealth to rapidly build up a new business model.
The company made the changes after its manufacturer rebates for insulin were challenged by the Federal Trade Commission. Among other shifts, Optum said 100% of all rebates will be distributed to customers by 2028.
Dallas-based MedCognetics and its academic R&D partners will have $750,000 more to spend refining diversity-calibrated AI for early detection of breast cancer, thanks to the NIH’s “AIM-AHEAD” initiative.
The executive branch of the European Union has launched a major project to aggregate cancer imaging data from across the continent so it can be readily tapped by healthcare providers, medical schools and industry innovators.
The American College of Radiology has worked out a way to protect patients from surprise medical bills for out-of-network services while modifying third-party arbitration so it sensibly serves providers and payers alike.
Johnson & Johnson has discontinued its Mosaico clinical trial that aimed to protect against HIV after its Phase 3 study revealed the regiment was safe but ineffective.
Promaxo Inc. of Oakland, Calif., sold eight of its systems for performing AI-equipped, MRI-guided prostate interventions in the fourth quarter of 2022. The company launched a year prior and has now topped $15 million in sales.